Legal & General Group Plc Acquires New Holdings in Bruker Corporation $BRKR

Legal & General Group Plc bought a new position in shares of Bruker Corporation (NASDAQ:BRKR) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 145,259 shares of the medical research company’s stock, valued at approximately $8,742,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in BRKR. Los Angeles Capital Management LLC bought a new position in shares of Bruker during the fourth quarter valued at $26,000. Allworth Financial LP grew its stake in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the last quarter. Essential Partners LLC bought a new stake in shares of Bruker in the first quarter worth $36,000. Global Retirement Partners LLC bought a new stake in shares of Bruker in the second quarter worth $38,000. Finally, Parallel Advisors LLC raised its position in Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on BRKR. Wall Street Zen upgraded shares of Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. TD Cowen restated a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Wolfe Research initiated coverage on Bruker in a report on Monday, June 1st. They set a “peer perform” rating for the company. Stifel Nicolaus set a $50.00 price target on Bruker in a report on Wednesday, August 5th. Finally, JPMorgan Chase & Co. lifted their price objective on Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $56.64.

Bruker Stock Performance

Shares of BRKR stock opened at $56.03 on Wednesday. The company has a market cap of $8.54 billion, a price-to-earnings ratio of -80.04, a price-to-earnings-growth ratio of 1.77 and a beta of 1.26. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $65.30. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The firm has a 50 day moving average of $58.82 and a 200-day moving average of $48.26.

Bruker (NASDAQ:BRKR) last released its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. During the same quarter in the previous year, the company earned $0.32 EPS. Bruker’s quarterly revenue was up 5.2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 21st. Bruker’s payout ratio is -28.57%.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.